- Home
- DHY vs AVIR Comparison
DHY vs AVIR Comparison
Compare DHY & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHY
- AVIR
- Stock Information
- Founded
- DHY 1998
- AVIR 2012
- Country
- DHY United States
- AVIR United States
- Employees
- DHY N/A
- AVIR N/A
- Industry
- DHY Finance/Investors Services
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- DHY Finance
- AVIR Health Care
- Exchange
- DHY Nasdaq
- AVIR Nasdaq
- Market Cap
- DHY 221.5M
- AVIR 247.5M
- IPO Year
- DHY N/A
- AVIR 2020
- Fundamental
- Price
- DHY $2.16
- AVIR $3.29
- Analyst Decision
- DHY
- AVIR Hold
- Analyst Count
- DHY 0
- AVIR 1
- Target Price
- DHY N/A
- AVIR $6.88
- AVG Volume (30 Days)
- DHY 569.1K
- AVIR 491.5K
- Earning Date
- DHY 01-01-0001
- AVIR 11-07-2024
- Dividend Yield
- DHY 9.10%
- AVIR N/A
- EPS Growth
- DHY N/A
- AVIR N/A
- EPS
- DHY N/A
- AVIR N/A
- Revenue
- DHY N/A
- AVIR N/A
- Revenue This Year
- DHY N/A
- AVIR N/A
- Revenue Next Year
- DHY N/A
- AVIR N/A
- P/E Ratio
- DHY N/A
- AVIR N/A
- Revenue Growth
- DHY N/A
- AVIR N/A
- 52 Week Low
- DHY $1.77
- AVIR $2.75
- 52 Week High
- DHY $2.08
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- DHY 37.02
- AVIR 49.07
- Support Level
- DHY $2.20
- AVIR $3.10
- Resistance Level
- DHY $2.17
- AVIR $3.27
- Average True Range (ATR)
- DHY 0.03
- AVIR 0.16
- MACD
- DHY -0.01
- AVIR 0.02
- Stochastic Oscillator
- DHY 5.00
- AVIR 55.28
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company with the objective to seek high current income and capital appreciation as a secondary objective.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).